This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Insights

Talking With Patients Who Have Major Depressive Disorder About the Benefits and Risks Associated With Atypical Antipsychotics

Roueen Rafeyan, MD, DFAPA, FASAM; George I. Papakostas, MD; W. Clay Jackson, MD, DipTh; and Madhukar H. Trivedi, MD

Published: April 6, 2021


Learn how to talk with patients who have major depressive disorder about antipsychotic treatment in a way that is clear and balanced and addresses patients’ potential concerns about taking antipsychotic medication.


Read the eReport

Quick Links: Depression (MDD)

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...